1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Bayer Germany Reverse-Switches Phytohustil, Expands Iberogast

 
• By David Ridley

Bayer Vital is taking the unusual step to reverse-switch its Phytohustil range of herbal cough medicines in Germany, to strengthen the role of pharmacy in ensuring consumers access the right products for their needs. The company is also launching a new celandine-free addition to its embattled Iberograst brand of herbal gastrointestinal medicines. 

Pharmacy_Consultation
• Source: Shutterstock

Bayer Vital GmbH has made the unusual decision of reverse-switching its own products, in this case two out of three products in the Phytohustil range of herbal cough medicines it markets in Germany.

Currently available for self-selection outside pharmacy, Phytohustil Hustenreizstiller Sirup has been recommended by Germany’s Expert Advisory Committee for Pharmacy-Only Issues...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

AESGP Annual Meeting: Commission Must ‘Think Carefully’ Before Reverse-Switching Antimicrobials

 
• By David Ridley

If the European Commission is serious about improving the competitiveness of the European Union, it should ditch the idea of making commonly used OTC antimicrobials like thrush treatments and cold sore creams prescription-only, warns Greek Medicines Agency president Evangelos Manolopoulos

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By David Ridley

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 
• By Malcolm Spicer

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

More from Health

Germany’s PharmaSGP To Be Taken Private

 
• By Tom Gallen

Consumer health player PharmaSGP will be taken private by its biggest shareholder, FUTRUE.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.